Trifecta Capital Advisors LLC Has $88,000 Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Trifecta Capital Advisors LLC trimmed its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 96.6% in the fourth quarter, HoldingsChannel.com reports. The firm owned 124 shares of the biopharmaceutical company’s stock after selling 3,570 shares during the period. Trifecta Capital Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $88,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. State Street Corp raised its stake in shares of Regeneron Pharmaceuticals by 1.3% in the 3rd quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company’s stock valued at $5,153,603,000 after buying an additional 61,277 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in Regeneron Pharmaceuticals by 1.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 673,261 shares of the biopharmaceutical company’s stock worth $707,759,000 after purchasing an additional 11,499 shares in the last quarter. Swiss National Bank lifted its stake in Regeneron Pharmaceuticals by 0.6% during the third quarter. Swiss National Bank now owns 321,600 shares of the biopharmaceutical company’s stock worth $338,079,000 after purchasing an additional 2,000 shares during the period. Sumitomo Mitsui Trust Group Inc. boosted its holdings in Regeneron Pharmaceuticals by 0.4% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 302,616 shares of the biopharmaceutical company’s stock valued at $215,562,000 after purchasing an additional 1,108 shares in the last quarter. Finally, National Pension Service grew its stake in shares of Regeneron Pharmaceuticals by 17.0% in the 3rd quarter. National Pension Service now owns 223,617 shares of the biopharmaceutical company’s stock valued at $235,075,000 after purchasing an additional 32,457 shares during the period. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Stock Performance

Shares of Regeneron Pharmaceuticals stock opened at $713.25 on Tuesday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. Regeneron Pharmaceuticals, Inc. has a 52 week low of $642.00 and a 52 week high of $1,211.20. The firm has a fifty day moving average of $699.17 and a two-hundred day moving average of $878.35. The stock has a market capitalization of $77.98 billion, a price-to-earnings ratio of 18.63, a PEG ratio of 2.34 and a beta of 0.08.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86. The firm had revenue of $3.79 billion during the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the company earned $11.86 earnings per share. As a group, equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 20th will be given a $0.88 dividend. The ex-dividend date is Thursday, February 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.49%. Regeneron Pharmaceuticals’s dividend payout ratio is presently 2.30%.

Wall Street Analyst Weigh In

REGN has been the subject of several analyst reports. Oppenheimer cut their target price on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating for the company in a research report on Wednesday, November 6th. Royal Bank of Canada cut their price objective on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating for the company in a report on Friday, November 1st. Wells Fargo & Company lowered their target price on shares of Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a report on Friday, January 10th. UBS Group downgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and cut their price target for the company from $1,130.00 to $738.00 in a report on Thursday, January 16th. Finally, Piper Sandler decreased their price objective on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating on the stock in a research note on Monday, January 27th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $973.13.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.